Dysregulation of the epigenome in triple-negative breast cancers: Basal-like and claudin-low breast cancers express aberrant DNA hypermethylation

Experimental and Molecular Pathology

Volumn 95, Issue 3, 2013, Pages 276-287

  Roll, J Devon ^a   Rivenbark, Ashley G ^a   Sandhu, Rupninder ^a,c   Parker, Joel S ^a   Jones, Wendell D ^a,b   Carey, Lisa A ^a   Livasy, Chad A ^a   Coleman, William B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Expression Analysis   (United States)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

Aberrant DNA hypermethylation; Basal like breast cancer; Claudin low breast cancer; Triple negative breast cancer

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MUCIN 1; PROGESTERONE RECEPTOR; PROTEIN MYB; UVOMORULIN; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CDH1 GENE; CEACAM6 GENE; CONTROLLED STUDY; CST6 GENE; DNA METHYLATION; EPIGENETICS; ESR1 GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GNA11 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MARKER GENE; MUC1 GENE; MYB GENE; PROMOTER REGION; RECURRENCE FREE SURVIVAL; SCNN1A GENE; TFF3 GENE; TRIPLE NEGATIVE BREAST CANCER; BREAST; CLASSIFICATION; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

BREAST; DNA METHYLATION; EPIGENOMICS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884963049     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.09.001     Document Type: Article

References (86)

1. Abe M., Ohira M., Kaneda A., Yagi Y., Yamamoto S., Kitano Y., Takato T., Nakagawara A., Ushijima T. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res. 2005, 65:828-834.
2. Ai L., Kim W.J., Kim T.Y., Fields C.R., Massoll N.A., Robertson K.D., Brown K.D. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res. 2006, 66:7899-7909.
3. Arce C., Perez-Plasencia C., Gonzalez-Fierro A., de la Cruz-Hernandez E., Revilla-Vazquez A., Chavez-Blanco A., Trejo-Becerril C., Perez-Cardenas E., Taja-Chayeb L., Bargallo E., Villarreal P., Ramirez T., Vela T., Candelaria M., Camargo M.F., Robles E., Duenas-Gonzalez A. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One 2006, 1:e98.
4. Asch B.B., Barcellos-Hoff M.H. Epigenetics and breast cancer. J. Mammary Gland Biol. Neoplasia 2001, 6:151-152.
5. Bachman K.E., Rountree M.R., Baylin S.B. Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J. Biol. Chem. 2001, 276:32282-32287.
6. Badve S., Dabbs D.J., Schnitt S.J., Baehner F.L., Decker T., Eusebi V., Fox S.B., Ichihara S., Jacquemier J., Lakhani S.R., Palacios J., Rakha E.A., Richardson A.L., Schmitt F.C., Tan P.H., Tse G.M., Weigelt B., Ellis I.O., Reis-Filho J.S. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod. Pathol. 2011, 24:157-167.
7. Banerjee S., Reis-Filho J.S., Ashley S., Steele D., Ashworth A., Lakhani S.R., Smith I.E. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J. Clin. Pathol. 2006, 59:729-735.
8. Baylin S. DNA methylation and epigenetic mechanisms of carcinogenesis. Dev. Biol. (Basel) 2001, 106:85-87.
9. Baylin S.B. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. 2005, 2(Suppl. 1):S4-S11.
10. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 1998, 72:141-196.
11. Bediaga N.G., Acha-Sagredo A., Guerra I., Viguri A., Albaina C., Ruiz Diaz I., Rezola R., Alberdi M.J., Dopazo J., Montaner D., Renobales M., Fernandez A.F., Field J.K., Fraga M.F., Liloglou T., de Pancorbo M.M. DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res. 2010, 12:R77.
12. Benito M., Parker J., Du Q., Wu J., Xiang D., Perou C.M., Marron J.S. Adjustment of systematic microarray data biases. Bioinformatics 2004, 20:105-114.
13. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16:6-21.
14. Brueckner B., Lyko F. DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy. Trends Pharmacol. Sci. 2004, 25:551-554.
15. Brueckner B., Kuck D., Lyko F. DNA methyltransferase inhibitors for cancer therapy. Cancer J. 2007, 13:17-22.
16. Carey L.A. Directed therapy of subtypes of triple-negative breast cancer. Oncologist 2010, 15(Suppl. 5):49-56.
17. Carey L.A. Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer. J. Clin. Oncol. 2010, 28:361-363.
18. Carey L.A. Novel targets for triple-negative breast cancer. Clin. Adv. Hematol. Oncol. 2011, 9:678-680.
19. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., Karaca G., Troester M.A., Tse C.K., Edmiston S., Deming S.L., Geradts J., Cheang M.C., Nielsen T.O., Moorman P.G., Earp H.S., Millikan R.C. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
20. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., Ollila D.W., Sartor C.I., Graham M.L., Perou C.M. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007, 13:2329-2334.
21. Chavez-Blanco A., Perez-Plasencia C., Perez-Cardenas E., Carrasco-Legleu C., Rangel-Lopez E., Segura-Pacheco B., Taja-Chayeb L., Trejo-Becerril C., Gonzalez-Fierro A., Candelaria M., Cabrera G., Duenas-Gonzalez A. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int. 2006, 6:2.
22. Dulaimi E., Ibanez de Caceres I., Uzzo R.G., Al-Saleem T., Greenberg R.E., Polascik T.J., Babb J.S., Grizzle W.E., Cairns P. Promoter hypermethylation profile of kidney cancer. Clin. Cancer Res. 2004, 10:3972-3979.
23. Eads C.A., Lord R.V., Kurumboor S.K., Wickramasinghe K., Skinner M.L., Long T.I., Peters J.H., DeMeester T.R., Danenberg K.D., Danenberg P.V., Laird P.W., Skinner K.A. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res. 2000, 60:5021-5026.
24. Eden A., Gaudet F., Waghmare A., Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300:455.
25. Elias A.D. Triple-negative breast cancer: a short review. Am. J. Clin. Oncol. 2010, 33:637-645.
26. Feinberg A.P., Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92.
27. Feinberg A.P., Vogelstein B. Hypomethylation of ras oncogenes in primary human cancers. Biochem. Biophys. Res. Commun. 1983, 111:47-54.
28. Feinberg A.P., Vogelstein B. Alterations in DNA methylation in human colon neoplasia. Semin. Surg. Oncol. 1987, 3:149-151.
29. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., Leonhardt H., Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science 2003, 300:489-492.
30. Goelz S.E., Vogelstein B., Hamilton S.R., Feinberg A.P. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985, 228:187-190.
31. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
32. Harrell J.C., Prat A., Parker J.S., Fan C., He X., Carey L., Anders C., Ewend M., Perou C.M. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res. Treat. 2012, 132:523-535.
33. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003, 349:2042-2054.
34. Hess K.R., Anderson K., Symmans W.F., Valero V., Ibrahim N., Mejia J.A., Booser D., Theriault R.L., Buzdar A.U., Dempsey P.J., Rouzier R., Sneige N., Ross J.S., Vidaurre T., Gomez H.L., Hortobagyi G.N., Pusztai L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 2006, 24:4236-4244.
35. Hu Z., Fan C., Oh D.S., Marron J.S., He X., Qaqish B.F., Livasy C., Carey L.A., Reynolds E., Dressler L., Nobel A., Parker J., Ewend M.G., Sawyer L.R., Wu J., Liu Y., Nanda R., Tretiakova M., Ruiz Orrico A., Dreher D., Palazzo J.P., Perreard L., Nelson E., Mone M., Hansen H., Mullins M., Quackenbush J.F., Ellis M.J., Olopade O.I., Bernard P.S., Perou C.M. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96.
36. Jin B., Li Y., Robertson K.D. DNA methylation: superior or subordinate in the epigenetic hierarchy?. Genes Cancer 2011, 2:607-617.
37. Jones P.A., Laird P.W. Cancer epigenetics comes of age. Nat. Genet. 1999, 21:163-167.
38. Juergens R.A., Wrangle J., Vendetti F.P., Murphy S.C., Zhao M., Coleman B., Sebree R., Rodgers K., Hooker C.M., Franco N., Lee B., Tsai S., Delgado I.E., Rudek M.A., Belinsky S.A., Herman J.G., Baylin S.B., Brock M.V., Rudin C.M. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011, 1:598-607.
39. Jurkowska R.Z., Jurkowski T.P., Jeltsch A. Structure and function of mammalian DNA methyltransferases. ChemBioChem 2011, 12:206-222.
40. Kaneko Y., Sakurai S., Hironaka M., Sato S., Oguni S., Sakuma Y., Sato K., Sugano K., Saito K. Distinct methylated profiles in Helicobacter pylori dependent and independent gastric MALT lymphomas. Gut 2003, 52:641-646.
41. Klose R.J., Bird A.P. Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 2006, 31:89-97.
42. Lapidus R.G., Nass S.J., Butash K.A., Parl F.F., Weitzman S.A., Graff J.G., Herman J.G., Davidson N.E. Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res. 1998, 58:2515-2519.
43. Liang G., Salem C.E., Yu M.C., Nguyen H.D., Gonzales F.A., Nguyen T.T., Nichols P.W., Jones P.A. DNA methylation differences associated with tumor tissues identified by genome scanning analysis. Genomics 1998, 53:260-268.
44. Melki J.R., Vincent P.C., Clark S.J. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 1999, 59:3730-3740.
45. Millikan R.C., Newman B., Tse C.K., Moorman P.G., Conway K., Dressler L.G., Smith L.V., Labbok M.H., Geradts J., Bensen J.T., Jackson S., Nyante S., Livasy C., Carey L., Earp H.S., Perou C.M. Epidemiology of basal-like breast cancer. Breast Cancer Res. Treat. 2008, 109:123-139.
46. Momparler R.L. Cancer epigenetics. Oncogene 2003, 22:6479-6483.
47. Narayan A., Ji W., Zhang X.Y., Marrogi A., Graff J.R., Baylin S.B., Ehrlich M. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int. J. Cancer 1998, 77:833-838.
48. Network T.C.G.A. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
49. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., Hernandez-Boussard T., Livasy C., Cowan D., Dressler L., Akslen L.A., Ragaz J., Gown A.M., Gilks C.B., van de Rijn M., Perou C.M. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004, 10:5367-5374.
50. Oh D.S., Troester M.A., Usary J., Hu Z., He X., Fan C., Wu J., Carey L.A., Perou C.M. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J. Clin. Oncol. 2006, 24:1656-1664.
51. Perou C.M. Molecular stratification of triple-negative breast cancers. Oncologist 2011, 16(Suppl. 1):61-70.
52. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
53. Perreard L., Fan C., Quackenbush J.F., Mullins M., Gauthier N.P., Nelson E., Mone M., Hansen H., Buys S.S., Rasmussen K., Orrico A.R., Dreher D., Walters R., Parker J., Hu Z., He X., Palazzo J.P., Olopade O.I., Szabo A., Perou C.M., Bernard P.S. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 2006, 8:R23.
54. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., He X., Perou C.M. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12:R68.
55. Prat A., Adamo B., Cheang M.C., Anders C.K., Carey L.A., Perou C.M. Molecular characterization of Basal-like and non-Basal-like triple-negative breast cancer. Oncologist 2013, 18:123-133.
56. Rakha E.A., Reis-Filho J.S., Ellis I.O. Basal-like breast cancer: a critical review. J. Clin. Oncol. 2008, 26:2568-2581.
57. Reis-Filho J.S., Tutt A.N. Triple negative tumours: a critical review. Histopathology 2008, 52:108-118.
58. Rivenbark A.G., Jones W.D., Coleman W.B. DNA methylation-dependent silencing of CST6 in human breast cancer cell lines. Lab. Invest. 2006, 86:1233-1242.
59. Rivenbark A.G., Jones W.D., Risher J.D., Coleman W.B. DNA methylation-dependent epigenetic regulation of gene expression in MCF-7 breast cancer cells. Epigenetics 2006, 1:32-44.
60. Rivenbark A.G., Livasy C.A., Boyd C.E., Keppler D., Coleman W.B. Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions. Exp. Mol. Pathol. 2007, 83:188-197.
61. Roll J.D., Rivenbark A.G., Jones W.D., Coleman W.B. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol. Cancer 2008, 7:15.
62. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., Hess K.R., Stec J., Ayers M., Wagner P., Morandi P., Fan C., Rabiul I., Ross J.S., Hortobagyi G.N., Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005, 11:5678-5685.
63. Sandhu R., Rivenbark A.G., Coleman W.B. Enhancement of chemotherapeutic efficacy in hypermethylator breast cancer cells through targeted and pharmacologic inhibition of DNMT3b. Breast Cancer Res. Treat. 2012, 131:385-399.
64. Sandhu R., Rivenbark A.G., Coleman W.B. Loss of post-transcriptional regulation of DNMT3b by microRNAs: a possible molecular mechanism for the hypermethylation defect observed in a subset of breast cancer cell lines. Int. J. Oncol. 2012, 41:721-732.
65. Segura-Pacheco B., Perez-Cardenas E., Taja-Chayeb L., Chavez-Blanco A., Revilla-Vazquez A., Benitez-Bribiesca L., Duenas-Gonzalez A. Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine. J. Transl. Med. 2006, 4:32.
66. Shen L., Ahuja N., Shen Y., Habib N.A., Toyota M., Rashid A., Issa J.P. DNA methylation and environmental exposures in human hepatocellular carcinoma. J. Natl. Cancer Inst. 2002, 94:755-761.
67. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein Lonning P., Borresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10869-10874.
68. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C.M., Lonning P.E., Brown P.O., Borresen-Dale A.L., Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8418-8423.
69. Sotiriou C., Powles T.J., Dowsett M., Jazaeri A.A., Feldman A.L., Assersohn L., Gadisetti C., Libutti S.K., Liu E.T. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 2002, 4:R3.
70. Sotiriou C., Neo S.Y., McShane L.M., Korn E.L., Long P.M., Jazaeri A., Martiat P., Fox S.B., Harris A.L., Liu E.T. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10393-10398.
71. Strathdee G., Appleton K., Illand M., Millan D.W., Sargent J., Paul J., Brown R. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am. J. Pathol. 2001, 158:1121-1127.
72. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., Issa J.P. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:8681-8686.
73. Toyota M., Ahuja N., Suzuki H., Itoh F., Ohe-Toyota M., Imai K., Baylin S.B., Issa J.P. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 1999, 59:5438-5442.
74. Tsou J.A., Hagen J.A., Carpenter C.L., Laird-Offringa I.A. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002, 21:5450-5461.
75. Ueki T., Toyota M., Sohn T., Yeo C.J., Issa J.P., Hruban R.H., Goggins M. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000, 60:1835-1839.
76. van de Rijn M., Perou C.M., Tibshirani R., Haas P., Kallioniemi O., Kononen J., Torhorst J., Sauter G., Zuber M., Kochli O.R., Mross F., Dieterich H., Seitz R., Ross D., Botstein D., Brown P. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol. 2002, 161:1991-1996.
77. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., Parrish M., Atsma D., Witteveen A., Glas A., Delahaye L., van der Velde T., Bartelink H., Rodenhuis S., Rutgers E.T., Friend S.H., Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002, 347:1999-2009.
78. van Engeland M., Weijenberg M.P., Roemen G.M., Brink M., de Bruine A.P., Goldbohm R.A., van den Brandt P.A., Baylin S.B., de Goeij A.F., Herman J.G. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res. 2003, 63:3133-3137.
79. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
80. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., Talantov D., Timmermans M., Meijer-van Gelder M.E., Yu J., Jatkoe T., Berns E.M., Atkins D., Foekens J.A. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
81. Weigelt B., Hu Z., He X., Livasy C., Carey L.A., Ewend M.G., Glas A.M., Perou C.M., Van't Veer L.J. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 2005, 65:9155-9158.
82. Wetzels R.H., Holland R., van Haelst U.J., Lane E.B., Leigh I.M., Ramaekers F.C. Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast. Am. J. Pathol. 1989, 134:571-579.
83. Widschwendter M., Jones P.A. DNA methylation and breast carcinogenesis. Oncogene 2002, 21:5462-5482.
84. Yoo C.B., Cheng J.C., Jones P.A. Zebularine: a new drug for epigenetic therapy. Biochem. Soc. Trans. 2004, 32:910-912.
85. Yuecheng Y., Hongmei L., Xiaoyan X. Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin. Exp. Metastasis 2006, 23:65-74.
86. Zambrano P., Segura-Pacheco B., Perez-Cardenas E., Cetina L., Revilla-Vazquez A., Taja-Chayeb L., Chavez-Blanco A., Angeles E., Cabrera G., Sandoval K., Trejo-Becerril C., Chanona-Vilchis J., Duenas-Gonzalez A. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 2005, 5:44.